局限性前列腺癌局灶消融治疗与标准治疗的系统综述:证据局限与临床实践建议
由于临床异质性仅能定性合成,总体偏倚风险和混杂为中至高,证据确定性低,FT的理想实施应在临床试验或良好设计的前瞻性队列研究中进行。
要点
- 证据确定性低,FT与标准治疗比较的有效性存在显著不确定性。
- 一项RCT显示血管靶向光动力疗法(PDT)2年治疗失败率显著低于AS,但功能结局无差异且外部有效性存疑。
- 回顾性研究显示聚焦HIFU与机器人RP的3年治疗失败率无显著差异,且HIFU控尿和勃起功能恢复更优。
核心结论
- FT作为局限性前列腺癌主要治疗的比较有效性证据确定性低,存在显著不确定性。
- 在获得长期临床意义结局的高确定性证据前,FT理想情况下应在临床试验或良好设计的前瞻性队列研究中进行。
研究设计与样本
- 方案驱动、遵循PRISMA的系统综述,比较原发性FT(次全、局灶、半腺或部分消融)与标准选项(AS、RP或EBRT)。
- 由于临床异质性,仅能进行定性合成;进行了偏倚风险和混杂评估,符合条件的系统综述采用AMSTAR评价,并总结了正在进行的前瞻性比较研究。
主要发现
- 一项比较血管靶向局灶光动力疗法(PDT)与AS的RCT发现PDT在2年时治疗失败率显著更低,功能结局无差异,但PDT与更差的短暂不良事件相关,且外部有效性存疑。
- 一项比较聚焦HIFU与机器人RP的回顾性研究发现3年治疗失败率无显著差异,聚焦HIFU具有更好的控尿和勃起功能恢复。
- 两项使用SEER数据的回顾性队列研究比较局灶激光消融(FLA)与RP和EBRT,报告FLA的肿瘤学结局显著更差。
- 总体偏倚风险和混杂为中至高;主要研究的数据质量和适用性有限,原因包括临床异质性、偏倚风险、混杂、缺乏长期数据、结局指标不当和外部有效性差。
- 几乎所有系统综述均认为缺乏高确定性证据,大多数系统综述的置信度评级为低或极低;共鉴定出8项正在进行的前瞻性比较研究。
临床怎么用
- FT不应作为常规标准实践推荐。
- FT理想情况下应在临床试验或良好设计的前瞻性队列研究中进行。
局限性
- 证据确定性低,存在显著不确定性。
- 仅能进行定性合成,因临床异质性无法定量合并。
- 总体偏倚风险和混杂为中至高。
- 主要研究缺乏长期数据、结局指标不当且外部有效性差。
- 大多数系统综述置信度评级为低或极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The clinical effectiveness of focal therapy (FT) for localised prostate cancer (PCa) remains controversial. OBJECTIVE: To analyse the evidence base for primary FT for localised PCa via a systematic review (SR) to formulate clinical practice recommendations. EVIDENCE ACQUISITION: A protocol-driven, PRISMA-adhering SR comparing primary FT (sub-total, focal, hemi-gland, or partial ablation) versus standard options (active surveillance [AS], radical prostatectomy [RP], or external beam radiotherapy [EBRT]) was undertaken. Only comparative studies with ≥50 patients per arm were included. Primary outcomes included oncological, functional, and quality-of-life outcomes. Risk of bias (RoB) and confounding assessments were undertaken. Eligible SRs were reviewed and appraised (AMSTAR) and ongoing prospective comparative studies were summarised. EVIDENCE SYNTHESIS: Out of 1119 articles identified, four primary studies (1 randomised controlled trial [RCT] and 3 retrospective studies) recruiting 3961 patients and ten eligible SRs were identified. Only qualitative synthesis was possible owing to clinical heterogeneity. Overall, RoB and confounding were moderate to high. An RCT comparing vascular-targeted focal photodynamic therapy (PDT) with AS found a significantly lower rate of treatment failure at 2 yr with PDT. There were no differences in functional outcomes, although PDT was associated with worse transient adverse events. However, the external validity of the study was contentious. A retrospective study comparing focal HIFU with robotic RP found no significant differences in treatment failure at 3 yr, with focal HIFU having better continence and erectile function recovery. Two retrospective cohort studies using Surveillance, Epidemiology and End Results data compared focal laser ablation (FLA) against RP and EBRT, reporting significantly worse oncological outcomes for FLA. The overall data quality and applicability of the primary studies were limited because of clinical heterogeneity, RoB and confounding, lack of long-term data, inappropriate outcome measures, and poor external validity. Virtually all the SRs identified concluded that there was insufficient high-certainty evidence to make definitive conclusions regarding the clinical effectiveness of FT, with the majority of SRs judged to have a low or critically low confidence rating. Eight ongoing prospective comparative studies were identified. Ways of improving the evidence base are discussed. CONCLUSIONS: The certainty of the evidence regarding the comparative effectiveness of FT as a primary treatment for localised PCa was low, with significant uncertainties. Until higher-certainty evidence emerges from robust prospective comparative studies measuring clinically meaningful outcomes at long-term time points, FT should ideally be performed within clinical trials or well-designed prospective cohort studies. PATIENT SUMMARY: We examined the literature to determine the effectiveness of prostate-targeted treatment compared with standard treatments for untreated localised prostate cancer. There was no strong evidence showing that focal treatment compares favourably with standard treatments; consequently, focal treatment is not recommended for routine standard practice.
引用
- Bates AS, Ayers J, Kostakopoulos N, et al. A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. Eur Urol Oncol. 2021. PMID: 33423943. doi:10.1016/j.euo.2020.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。